Skip to content
bioinnovationbeacon.com

bioinnovationbeacon.com

  • Home
  • AI
  • Biotech News
  • Research
  • Technology
  • Press Releases
  • Privacy Policy
  • Contact Us

Transactions under Novonesis’ share buyback program

November 16, 2026byadmin
transactions-under-novonesis’-share-buyback-program

Please read the announcement in PDF

Attachment

  • 2026_29_Share_buyback

Globenewswire

Post navigation

Vivani Medical Announces Private Placement Equity Financing
CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Related Posts

seer-secures-key-victory-in-itc-patent-dispute-as-investigative-staff-backs-all-requested-remedies-against-nanomics
Seer Secures Key Victory in ITC Patent Dispute as Investigative Staff Backs All Requested Remedies Against Nanomics

ITC investigative staff recommends full exclusion and cease-and-desist orders sought by Seer REDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE)…

new-long-term-rhapsido-(remibrutinib)-phase-iii-data-show-sustained-efficacy-through-week-52-in-chronic-inducible-urticaria-(cindu)
New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)

RemIND data show clinically meaningful responses through Week 52 across three most prevalent CIndU subtypes, including after switching from placebo…

recordati-first-nine-months-2026:-net-revenue-+75%,-ebitda-+77%,-adjusted-net-income-+6.4%
RECORDATI FIRST NINE MONTHS 2026: NET REVENUE +7.5%, EBITDA +7.7%, ADJUSTED NET INCOME +6.4%

Consolidated net revenue of € 2,103.7 million in the first nine months of 2026, +7.5% or +9.4% on a like-for-like…

| Depth News by Ascendoor | Powered by WordPress.